Free Trial
→ Live demo of Elon Musk’s AI agent (From Brownstone Research) (Ad)tc pixel Free CALT Stock Alerts

Calliditas Therapeutics AB (publ) (CALT) Competitors

Calliditas Therapeutics AB (publ) logo
$40.00 0.00 (0.00%)
As of 06/9/2026
Compare

CALT vs. LEGN, NNNN, EWTX, ERAS, and INDV

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? MarketBeat compares Calliditas Therapeutics AB (publ) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calliditas Therapeutics AB (publ) include Legend Biotech (LEGN), Anbio Biotechnology (NNNN), Edgewise Therapeutics (EWTX), Erasca (ERAS), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

How does Calliditas Therapeutics AB (publ) compare to Legend Biotech?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Legend Biotech has a consensus target price of $60.23, indicating a potential upside of 72.78%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Legend Biotech is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Legend Biotech
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Legend Biotech had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Legend Biotech and 0 mentions for Calliditas Therapeutics AB (publ). Legend Biotech's average media sentiment score of 0.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
Legend Biotech Positive

Legend Biotech has a net margin of -21.98% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Legend Biotech's return on equity of -24.92% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
Legend Biotech -21.98%-24.92%-14.87%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
Legend Biotech$1.03B6.29-$296.80M-$0.68N/A

Summary

Legend Biotech beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Anbio Biotechnology?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, indicating that its share price is 338% more volatile than the broader market.

Anbio Biotechnology has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Anbio Biotechnology's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
Anbio Biotechnology N/A N/A N/A

Anbio Biotechnology has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
Anbio Biotechnology$8.65M273.31$6.40MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Anbio Biotechnology had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Anbio Biotechnology and 0 mentions for Calliditas Therapeutics AB (publ). Anbio Biotechnology's average media sentiment score of 1.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
Anbio Biotechnology Very Positive

Summary

Anbio Biotechnology beats Calliditas Therapeutics AB (publ) on 9 of the 12 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Edgewise Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Edgewise Therapeutics' return on equity of -32.55% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Edgewise TherapeuticsN/A -32.55% -31.04%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Edgewise Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/A-$167.79M-$1.66N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Edgewise Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Edgewise Therapeutics presently has a consensus price target of $44.22, suggesting a potential upside of 34.33%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Edgewise Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edgewise Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Edgewise Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Edgewise Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 beat Edgewise Therapeutics' score of -0.14 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.

Company Overall Sentiment
Edgewise Therapeutics Neutral
Calliditas Therapeutics AB (publ) Neutral

Summary

Edgewise Therapeutics beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Erasca?

Erasca (NASDAQ:ERAS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Erasca has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

In the previous week, Erasca had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Erasca and 0 mentions for Calliditas Therapeutics AB (publ). Erasca's average media sentiment score of 0.93 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Erasca is being referred to more favorably in the media.

Company Overall Sentiment
Erasca Positive
Calliditas Therapeutics AB (publ) Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Erasca. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ErascaN/AN/A-$124.55M-$0.93N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Erasca has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Erasca's return on equity of -35.31% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
ErascaN/A -35.31% -29.49%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

67.8% of Erasca shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Erasca currently has a consensus target price of $20.11, suggesting a potential upside of 50.42%. Given Erasca's stronger consensus rating and higher probable upside, equities research analysts plainly believe Erasca is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Erasca
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Erasca beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Indivior (NASDAQ:INDV) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Indivior has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Indivior has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior$1.24B3.75$210M$1.9519.53
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

60.3% of Indivior shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Indivior had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 0.21 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the media.

Company Overall Sentiment
Indivior Neutral
Calliditas Therapeutics AB (publ) Neutral

Indivior presently has a consensus price target of $39.33, indicating a potential upside of 3.26%. Given Indivior's stronger consensus rating and higher possible upside, equities research analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Indivior has a net margin of 19.44% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior19.44% -219.26% 29.40%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

Summary

Indivior beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALT vs. The Competition

Export
MetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.19B$766.77M$6.50B$11.95B
Dividend YieldN/A4.84%2.67%5.61%
P/E Ratio-21.621.4624.6523.63
Price / Sales0.74127.47498.98103.49
Price / CashN/A20.0643.0554.72
Price / Book37.747.9310.436.70
Net Income-$43.96M-$4.69M$3.56B$337.26M
7 Day PerformanceN/A-1.57%-1.39%-1.41%
1 Month PerformanceN/A3.42%0.86%1.15%
1 Year PerformanceN/A91.59%19.42%22.61%

Calliditas Therapeutics AB (publ) Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat		N/AN/A$1.19B$1.60BN/A180
LEGN
Legend Biotech
4.4046 of 5 stars		$36.28
+42.2%		$59.15
+63.0%		-3.7%$4.74B$1.03BN/A2,965
NNNN
Anbio Biotechnology
1.5491 of 5 stars		$32.12
+6.5%		N/AN/A$4.34B$8.65MN/A27
EWTX
Edgewise Therapeutics
2.3172 of 5 stars		$37.25
-7.5%		$44.22
+18.7%		+123.2%$4.33BN/AN/A60
ERAS
Erasca
2.898 of 5 stars		$13.48
-2.5%		$18.75
+39.1%		+722.7%$4.30BN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners
OpenAI is preparing to go public
OpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Important SpaceX PREDICTION
The biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...
Banyan Hill Publishing | Sponsoredtc pixel